Issues in cervical cancer incidence and treatment in HIV
- 1 September 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 22 (5), 449-455
- https://doi.org/10.1097/cco.0b013e32833cff4f
Abstract
Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.Keywords
This publication has 52 references indexed in Scilit:
- Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) Positivity in Cervical Cancer Screening of Women in a Peri-Urban Area in Andhra Pradesh, IndiaCancer Epidemiology, Biomarkers & Prevention, 2010
- Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlookCurrent Opinion in Oncology, 2009
- Does HIV/AIDS Have a Biological Impact on the Risk of Human Papillomavirus–Related Cancers?JNCI Journal of the National Cancer Institute, 2009
- Risk of Human Papillomavirus–Associated Cancers Among Persons With AIDSJNCI Journal of the National Cancer Institute, 2009
- Pattern of cancer risk in persons with AIDS in Italy in the HAART eraBritish Journal of Cancer, 2009
- Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical CancerThe Journal of Infectious Diseases, 2009
- Associations of Insulin‐Like Growth Factor (IGF)–I and IGF‐Binding Protein–3 with HIV Disease Progression in WomenThe Journal of Infectious Diseases, 2008
- Cervical cancer screening using visual inspection with acetic acid: operational experiences from Ghana and ThailandReproductive Health Matters, 2008
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI Journal of the National Cancer Institute, 2005
- Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test ResultsJama-Journal Of The American Medical Association, 2005